Jagrut Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 03-12-2024
- Paid Up Capital ₹ 0.99 M
as on 03-12-2024
- Company Age 15 Year, 6 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 1.50 Cr
as on 03-12-2024
About Jagrut Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.99 M.
The company currently has active open charges totaling ₹1.50 Cr.
Satish Vyas, Ritesh Vyas, Deepak Vyas, and One other member serve as directors at the Company.
- CIN/LLPIN
U33100MH2009PTC194151
- Company No.
194151
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jul 2009
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jagrut Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ritesh Vyas  | Managing Director | 17-Jul-2009 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Satish Vyas | Director | 17-Jul-2009 | Current |
| Deepak Vyas | Director | 17-Jul-2009 | Current |
| Mithun Vyas | Director | 17-Jul-2009 | Current |
Financial Performance of Jagrut Pharmaceuticals.
Enhance accessibility to Jagrut Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Jagrut Pharmaceuticals?
In 2019, Jagrut Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jagrut Hotels Private LimitedActive 12 years 3 monthsSatish Vyas, Ritesh Vyas and 2 more are mutual person
Charges (Loans)
₹15.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 1.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Mar 2019 | Others | ₹1.50 Cr | Open |
How Many Employees Work at Jagrut Pharmaceuticals?
Unlock and access historical data on people associated with Jagrut Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jagrut Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jagrut Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.